Aza Technology Inc Profile last edited on: 7/10/24
CAGE: 7KF03
UEI: PSKJTVPT3169
Business Identifier: Point-of-care devices for diagnosing and managing hyperammonemia, Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Multiple
Congr. District: 16
County: Santa Clara
Congr. District: 16
County: Santa Clara
Public Profile
A startup spun out of Stanford, Aza Technology is described as poised to deliver point-of-care device targeting diagnosis and management of hyperammonemia - responsible for a host of neurotoxic effects seen in Urea Cycle Disorder (UCD) and organic acidemia (OA) patients. Hyperammonemia is also referenced as a root cause of hepatic encephalopathy - a serious condition secondary only to alcoholic and non-alcoholic cirrhosis (NASH), resulting in over $2 billion in hospitalizations in the US alone. The foundational intellectual property under development at Aza Technology is described as enabling a home-use and point-of-care diagnostic device for evaluation of blood ammonia levels. In concert with their physicians, end-users would have capability to treat their own ammonia elevations with their choice of several safe and effective therapeutics.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
5-9Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2021 | 1 | NIH | $229,542 | |
Project Title: Point-of-Care Blood Ammonia Measurement Using a Gas-Phase Fuel Cell Sensor |
Key People / Management
Thomas Richard Veltman -- CEO, President and CYO
Company News
There are no news available.